Form 4: Puma Biotechnology Executive Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Jeffrey Jerome Ludwig, Chief Commercial Officer of Puma Biotechnology, sold 2,598 shares of common stock at an average price of $3.7011 under a pre-arranged 10b5-1 trading plan.
Summary
- On July 17, 2024, Jeffrey Jerome Ludwig, the Chief Commercial Officer of Puma Biotechnology, sold 2,598 shares of the company's common stock.
- The sale was executed under a pre-existing 10b5-1 trading plan adopted on December 14, 2020.
- The shares were sold at a weighted average price of $3.7011, with individual transaction prices ranging from $3.6001 to $3.8901.
- Following the transaction, Ludwig directly owns 118,388 shares of Puma Biotechnology.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock sale by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
Sales by company executives are a common occurrence and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some investors, potentially leading to slight downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| 12-14-2020 | Adoption date of the 10b5-1(c) sell to cover program. |
| 07/17/2024 | Date of the transaction (sale of shares). |
| 07/18/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.